Bambusa Therapeutics
Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders
Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders
Actionable Insights Powered by AI
Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders